<DOC>
	<DOCNO>NCT00874926</DOCNO>
	<brief_summary>The aim international prospective , non-interventional post-marketing surveillance study obtain data treatment procedure , long-term safety efficacy patient acceptance KOGENATE Bayer treatment patient haemophilia A daily-life treatment condition .</brief_summary>
	<brief_title>EFFEKT - Efficacy Safety Long-term Treatment With KOGENATE Bayer/FS</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Patients diagnosis haemophilia A , treated KOGENATE Bayer/FS source FVIII , decision take investigator administer KOGENATE Bayer/FS . For pretreated patient 100 exposure day inhibitor assessment within three month prior enrollment available ; pretreated patient less 100 exposure day inhibitor assessment baseline available . Exclusion criterion must read conjunction local product information .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Octocog alfa</keyword>
	<keyword>Haemophilia A</keyword>
</DOC>